PUBLISHER: Grand View Research | PRODUCT CODE: 1433659
PUBLISHER: Grand View Research | PRODUCT CODE: 1433659
U.S. Minor Cannabinoids Market Size, Share & Trends Analysis Report By Product (Cannabigerol (CBG), Tetrahydrocannabivarin (THCV), Cannabichromene (CBC)), By Application (Cancer, Inflammation, Neurological Disorders),& Segment Forecasts, 2024 - 2030
U.S. Minor Cannabinoids Market Growth & Trends:
The U.S. minor cannabinoids market size is expected to reach USD 33.3 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.0% from 2024 to 2030. Rising use of cannabinoid-based products and awareness regarding the health benefits associated with cannabinoid consumption are some of the crucial factors supporting the growth.
Minor cannabinoids have potential therapeutic benefits, including anti-inflammatory, analgesic, and neuroprotective effects. There is a growing interest in developing pharmaceuticals and nutraceuticals containing minor cannabinoids for the treatment of various medical conditions, such as chronic pain, anxiety, and sleep disorders. For instance, in January 2021, Lygos, Inc. announced the commercial availability of cannabichromene (CBC) that has a wide range of anti-inflammatory, antioxidant, and pain management properties.
Wellness products such as supplements, tinctures, and topicals incorporate minor cannabinoids. These products are marketed as natural remedies for various health issues, and are becoming popular among consumers who are looking for alternatives to traditional medications. For instance, Nextraction, a supplier of personal care and health & wellness products, launched Kriva-a range of Cannabinol (CBN), cannabidiol acid (CBDA), and Cannabigerolic acid (CBGA)-in topical and ingestible formulas.
Various organic and inorganic developments done by key players to strengthen their business avenues and footprints in the U.S. minor cannabinoids industry are anticipated to facilitate market expansion over the forecast period. In October 2022, Purissima, Inc., a biotechnology company in partnership with Open Book Extracts (OBX), launched its first fermentation-derived natural CBC products such as gummies, topical serums, tinctures, and capsules.
U.S. Minor Cannabinoids Market Report Highlights:
- Based on product type, the tetrahydrocannabivarin (THCV) segment dominated the market with a revenue share of 25.9% in 2023, owing to increasing application of THCV in the management of conditions such as arthritis, metabolic disorders, and epilepsy
- Based on application, the neurological disorders segment accounted for a significant revenue share in 2023, due to the rising prevalence of neurological disorders and applications of cannabinoids in their management
- Some of the major market players include GCM Holdings (Global Cannabinoids), LLC, GenCanna, Mile High Labs, ZERO POINT EXTRACTION, LLC, BulKanna, and CBD. INC.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product Type
- 1.2.2. Application
- 1.2.3. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product type outlook
- 2.2.2. Application outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Minor Cannabinoids Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. U.S. Minor Cannabinoids Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.1. Industry Analysis - Porter's
Chapter 4. U.S. Minor Cannabinoids Market: Product Type Estimates & Trend Analysis
- 4.1. Product Type Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. U.S. Minor Cannabinoids Market by Product Type Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Cannabigerol (CBG)
- 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.2. Cannabichromene (CBC)
- 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.3. Cannabinol (CBN)
- 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.4. Tetrahydrocannabivarin (THCV)
- 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.5. Cannabigerolic acid (CBGA)
- 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.6. Others
- 4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.1. Cannabigerol (CBG)
Chapter 5. U.S. Minor Cannabinoids Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global U.S. Minor Cannabinoids Market by Application Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Inflammation
- 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.2. Pain Management
- 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3. Neurological Disorders
- 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.4. Cancer
- 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.5. Others
- 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.1. Inflammation
Chapter 6. Competitive Landscape
- 6.1. Recent Developments & Impact Analysis, By Key Market Participants
- 6.2. Company/Competition Categorization
- 6.3. Vendor Landscape
- 6.3.1. Mile High Labs
- 6.3.1.1. Company overview
- 6.3.1.2. Financial performance
- 6.3.1.3. Product benchmarking
- 6.3.1.4. Strategic initiatives
- 6.3.2. GCM Holdings, LLC
- 6.3.2.1. Company overview
- 6.3.2.2. Financial performance
- 6.3.2.3. Product benchmarking
- 6.3.2.4. Strategic initiatives
- 6.3.3. GenCanna.
- 6.3.3.1. Company overview
- 6.3.3.2. Financial performance
- 6.3.3.3. Product benchmarking
- 6.3.3.4. Strategic initiatives
- 6.3.4. CBD. INC.
- 6.3.4.1. Company overview
- 6.3.4.2. Financial performance
- 6.3.4.3. Product benchmarking
- 6.3.4.4. Strategic initiatives
- 6.3.5. Rhizo Sciences
- 6.3.5.1. Company overview
- 6.3.5.2. Financial performance
- 6.3.5.3. Product benchmarking
- 6.3.5.4. Strategic initiatives
- 6.3.6. Laurelcrest
- 6.3.6.1. Company overview
- 6.3.6.2. Financial performance
- 6.3.6.3. Product benchmarking
- 6.3.6.4. Strategic initiatives
- 6.3.7. Fresh Bros Hemp Company
- 6.3.7.1. Company overview
- 6.3.7.2. Financial performance
- 6.3.7.3. Product benchmarking
- 6.3.7.4. Strategic initiatives
- 6.3.8. BulKanna
- 6.3.8.1. Company overview
- 6.3.8.2. Financial performance
- 6.3.8.3. Product benchmarking
- 6.3.8.4. Strategic initiatives
- 6.3.9. High Purity Natural Products
- 6.3.9.1. Company overview
- 6.3.9.2. Financial performance
- 6.3.9.3. Product benchmarking
- 6.3.9.4. Strategic initiatives
- 6.3.10. ZERO POINT EXTRACTION, LLC
- 6.3.10.1. Company overview
- 6.3.10.2. Financial performance
- 6.3.10.3. Product benchmarking
- 6.3.10.4. Strategic initiatives
- 6.3.1. Mile High Labs
List of Tables
- Table 1 List of abbreviations
- Table 2 U.S. minor cannabinoids market, by product type, 2018 - 2030 (USD Million)
- Table 3 U.S. minor cannabinoids market, by application, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value-chain-based sizing & forecasting
- Fig. 6 QFD modeling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 U.S. minor cannabinoids market: market outlook
- Fig. 9 U.S. minor cannabinoids competitive insights
- Fig. 10 Parent market outlook
- Fig. 11 Related/ancillary market outlook
- Fig. 12 Penetration and growth prospect mapping
- Fig. 13 Industry value chain analysis
- Fig. 14 U.S. minor cannabinoids market driver impact
- Fig. 15 U.S. minor cannabinoids market restraint impact
- Fig. 16 U.S. minor cannabinoids market strategic initiatives analysis
- Fig. 17 U.S. minor cannabinoids market: Product type movement analysis
- Fig. 18 U.S. minor cannabinoids market: Product type outlook and key takeaways
- Fig. 19 Cannabigerol (CBG)market estimates and forecast, 2018 - 2030
- Fig. 20 Cannabichromene (CBC) market estimates and forecast, 2018 - 2030
- Fig. 21 Cannabinol (CBN) market estimates market and forecast, 2018 - 2030
- Fig. 22 Tetrahydrocannabivarin (THCV) market estimates and forecast, 2018 - 2030
- Fig. 23 Cannabigerolic acid (CBGA) market estimates and forecast, 2018 - 2030
- Fig. 24 Others (Cannabidiolic Acid (CBDA), Cannabidivarin (CBDV), And Other Minor Cannabinoids) estimates and forecast, 2018 - 2030
- Fig. 25 U.S. minor cannabinoids market: Application movement Analysis
- Fig. 26 U.S. minor cannabinoids market: Application outlook and key takeaways
- Fig. 27 Inflammation market estimates and forecasts, 2018 - 2030
- Fig. 28 Pain management market estimates and forecasts, 2018 - 2030
- Fig. 29 Neurological disorders market estimates and forecasts,2 018 - 2030
- Fig. 30 Cancer market estimates and forecasts, 2018 - 2030
- Fig. 31 Others market estimates and forecasts, 2018 - 2030
